🎉 M&A multiples are live!
Check it out!

AnaptysBio Valuation Multiples

Discover revenue and EBITDA valuation multiples for AnaptysBio and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

AnaptysBio Overview

About AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).


Founded

2005

HQ

United States of America
Employees

136

Website

anaptysbio.com

Financials

LTM Revenue $79.0M

LTM EBITDA -$113M

EV

$178M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

AnaptysBio Financials

AnaptysBio has a last 12-month revenue of $79.0M and a last 12-month EBITDA of -$113M.

In the most recent fiscal year, AnaptysBio achieved revenue of $91.3M and an EBITDA of -$92.7M.

AnaptysBio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See AnaptysBio valuation multiples based on analyst estimates

AnaptysBio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $17.2M $91.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$143M -$92.7M XXX XXX XXX
EBITDA Margin -834% -102% XXX XXX XXX
Net Profit -$129M -$164M XXX XXX XXX
Net Margin -750% -179% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

AnaptysBio Stock Performance

As of April 15, 2025, AnaptysBio's stock price is $18.

AnaptysBio has current market cap of $548M, and EV of $178M.

See AnaptysBio trading valuation data

AnaptysBio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$178M $548M XXX XXX XXX XXX $-5.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

AnaptysBio Valuation Multiples

As of April 15, 2025, AnaptysBio has market cap of $548M and EV of $178M.

AnaptysBio's trades at 2.3x LTM EV/Revenue multiple, and -1.6x LTM EBITDA.

Analysts estimate AnaptysBio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for AnaptysBio and 10K+ public comps

AnaptysBio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $178M XXX XXX XXX
EV/Revenue 2.0x XXX XXX XXX
EV/EBITDA -1.9x XXX XXX XXX
P/E -3.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get AnaptysBio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

AnaptysBio Valuation Multiples

AnaptysBio's NTM/LTM revenue growth is -32%

AnaptysBio's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $1.5M for the same period.

Over next 12 months, AnaptysBio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate AnaptysBio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for AnaptysBio and other 10K+ public comps

AnaptysBio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 432% XXX XXX XXX XXX
EBITDA Margin -102% XXX XXX XXX XXX
EBITDA Growth -35% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -133% XXX XXX XXX XXX
Revenue per Employee $0.7M XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 46% XXX XXX XXX XXX
R&D Expenses to Revenue 179% XXX XXX XXX XXX
Opex to Revenue 226% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

AnaptysBio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

AnaptysBio M&A and Investment Activity

AnaptysBio acquired  XXX companies to date.

Last acquisition by AnaptysBio was  XXXXXXXX, XXXXX XXXXX XXXXXX . AnaptysBio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by AnaptysBio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About AnaptysBio

When was AnaptysBio founded? AnaptysBio was founded in 2005.
Where is AnaptysBio headquartered? AnaptysBio is headquartered in United States of America.
How many employees does AnaptysBio have? As of today, AnaptysBio has 136 employees.
Who is the CEO of AnaptysBio? AnaptysBio's CEO is Mr. Daniel R. Faga.
Is AnaptysBio publicy listed? Yes, AnaptysBio is a public company listed on NAS.
What is the stock symbol of AnaptysBio? AnaptysBio trades under ANAB ticker.
When did AnaptysBio go public? AnaptysBio went public in 2017.
Who are competitors of AnaptysBio? Similar companies to AnaptysBio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of AnaptysBio? AnaptysBio's current market cap is $548M
What is the current revenue of AnaptysBio? AnaptysBio's last 12-month revenue is $79.0M.
What is the current EBITDA of AnaptysBio? AnaptysBio's last 12-month EBITDA is -$113M.
What is the current EV/Revenue multiple of AnaptysBio? Current revenue multiple of AnaptysBio is 2.3x.
What is the current EV/EBITDA multiple of AnaptysBio? Current EBITDA multiple of AnaptysBio is -1.6x.
What is the current revenue growth of AnaptysBio? AnaptysBio revenue growth between 2023 and 2024 was 432%.
Is AnaptysBio profitable? Yes, AnaptysBio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.